PRMT5-IN-34

Cat. No.:	HY-158143
Molecular Formula:	$C_{23}H_{19}F_2N_5O_2$
Molecular Weight:	435.43
Target:	Histone Methyltransferase
Pathway:	Epigenetics
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	PRMT5-IN-34 (Compound C) is an inhibitor of MTA-cooperative Protein arginine methyltransferase 5 (PRMT5/MAT)[1].
IC_{50} & Target	PRMT5
In Vitro	PRMT5-IN-34 inhibits each cell proliferation activity with IC_{50}=0.827 μM (HDLM2), 0.252 μM (L540), 0.077 μM (L1236), 4.638 μM (L428), 0.170 μM (HCT116), 8.538 μM (HCT116) and 0.538 μM (HCT116), respectively[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo	PRMT5-IN-34 (p.o.; 25-100 mg/kg; once daily for 21 days) inhibits tumor growth and decreases SDMA protein levels in the MTAP-silenced L540HL xenograft mouse model[1]. MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	MTAP silenced L540 HL xenograft model [1]
Dosage:	25; 50; 100 mg/kg
Administration:	p.o. once daily for 21 days
Result:	Concentration-dependently inhibited tumor growth (22%, 52%, 93%). Concentration-dependently decreased the protein level of SDMA (83.9%, 97.6%, 99.1%).

REFERENCES

[1]. James T et al. Methylthioadenosine (MTA)-cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors for use in the treatment of cancer that is wild type MTAP gene silenced. World Intellectual Property Organization, WO2024038004 A1 2024-02-22

Tel: 609-228-6898 Fax: 609-228-5909 E-mail: tech@MedChemExpress.com
Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA